Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (355)	1/5/1999 10:38:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1073

ask 7, 1000 CRGN purchased for each portfolio (eom)

To: scaram(o)uche who wrote (355)	1/5/1999 9:07:00 PM
From: JMarcus	Read Replies (2) \| Respond to of 1073

Any idea whether or not CEGE and AVGN have an actual or possible patent conflict? AVGN has filed for an IND for its AAV vector to treat hemophilia. biz.yahoo.com In a presentation at an Informed Investor workshop this past summer, the presenter from Avigen said that Avigen had spent many years and lots of money developing a proprietary technique for producing clinical grade AAV vectors in commercial quantities. He said that this had been a very significant technological challenge and that Avigen's solution to it was what gave them their edge over the competition. It would be most interesting to hear from both CEGE and Avigen what each thinks about the other's foray into the field.